Skip to content
Companies

Linnaeus Therapeutics

Oral estrogen receptor agonist for melanoma

Raised to date

$6.3M

of $20M offered across 5 Form D filings

Still open
$13.7M
Investors
25
Last filed
Apr 2, 2026

About

Linnaeus Therapeutics is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for oncology. The company's lead program targets the G protein-coupled estrogen receptor (GPER) to activate tumor-suppressive pathways, aiming to treat cancers like melanoma, particularly in patients who do not respond to existing immunotherapies.

The company's approach is rooted in discoveries from the University of Pennsylvania, targeting the GPER receptor which is a novel mechanism in oncology. This strategy is coupled with a predictive biomarker to identify patients most likely to benefit, addressing a significant unmet need for those intolerant to traditional immunotherapy.

Funding

Aug 2025Feb 2026
Now

$10M round, first sold Feb 2026: $5M sold, $5M still open

  • EquityFiled Apr 2, 2026Form D/A
    $5M/ $10M
  • EquityFiled Mar 31, 2026Form D/A
    $4.9M/ $10M
  • EquityFiled Mar 13, 2026Form D/A
    $4.8M/ $10M
  • EquityFiled Feb 27, 2026Form D
    $4.5M/ $10M
  • Security to be acquiredFiled Aug 22, 2025Form D
    $1.3M/ $10M

Product

LNS8801

Small-Molecule Therapeutic

LNS8801 is an orally administered, small-molecule agonist of the G protein-coupled estrogen receptor (GPER). It is being developed for cancer treatment and functions by rapidly depleting c-Myc protein levels, leading to antitumor activity and demonstrating target engagement in clinical trials.

  • Oral small-molecule agonist of GPER
  • Rapidly depletes c-Myc protein levels to induce antitumor activity
  • Has shown durable clinical benefit in trials

Built for

Patients with advanced, treatment-refractory cancers, specifically those with metastatic cutaneous melanoma.

People on file